靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2008-09-01 |
A dose ranging study investigating the efficacy and safety of sublingualimmunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen season, administered as allergen based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis (with or without asthma)
A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from house dust mite allergic rhinitis
100 项与 Stallergenes SAS 相关的临床结果
0 项与 Stallergenes SAS 相关的专利(医药)
100 项与 Stallergenes SAS 相关的药物交易
100 项与 Stallergenes SAS 相关的转化医学